Left Ventricular Function

At 1 year, leaflet transcatheter mitral valve repair demonstrated low rate of complications, high survival and sustained mitral regurgitation reduction, according to results of the CLASP study presented at the virtual PCR e-course.

In HF with reduced ejection fraction, factors such as HF duration, nonischemic cardiomyopathy and no coronary disease may be linked to improvements in left ventricular ejection fraction and better outcomes, researchers reported.

Patients with increases in left ventricular diastolic pressures after successful transcatheter aortic valve replacement had elevated risk for adverse outcomes, according to data presented at the American College of Cardiology Scientific Session.

Patients with severely reduced left ventricular ejection fraction and CAD who underwent PCI had higher rates of MACE and mortality compared with those who underwent CABG, according to a study published in JAMA Cardiology.

Compared with men, women had increased flow and cardiac strain parameters associated with left ventricular mass, according to a study published in Radiology: Cardiothoracic Imaging.

Abbott announced its fully implantable left ventricular assist system received a breakthrough device designation from the FDA.

Patients who regularly used cannabis were more likely to have adverse changes in subclinical dysfunction and left ventricular size compared with those who rarely or never used the substance, according to a study published in JACC: Cardiovascular Imaging.

PHILADELPHIA — Patients with obstructive hypertrophic cardiomyopathy who were treated with mavacamten for 1 year had improvements in left ventricular outflow tract gradients, symptoms and N-terminal pro-B-type natriuretic peptide, according to data presented at the American Heart Association Scientific Sessions.

Medtronic announced it has received a breakthrough device designation from the FDA for its fully implantable left ventricular assist device for patients with advanced HF.

SAN FRANCISCO — Early clinical data suggest that an investigational percutaneous device designed to directly repair the left ventricle is feasible and safe in patients with HF and functional mitral regurgitation. Data on the first 31 patients enrolled in the CorCinch FMR early feasibility study who were treated with the AccuCinch ventricular repair system at U.S. centers through July were presented at TCT 2019.